Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

Pfizer

Status and phase: Completed; Phase 2

Conditions: Breast Neoplasms

Treatments: Drug: exemestane (Aromasin®)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00174343

971-ONC-0028-095

Details and patient eligibility

About

To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Post-menopausal patients with unilateral breast cancer T2 to T4, N0-1, M0, non inflammatory, operable, hormonal receptors positive

Exclusion criteria

• Patients with bilateral breast cancer T4d, inflammatory, non operable, hormonal receptors negative

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)